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Translational relevance
The presence of a conspicuous local inflammatory reaction is associated with improved survival of patients with colorectal cancer independent of stage, whereas the presence of elevated systemic inflammatory responses, as measured by acute phase proteins, is associated with decreased survival. One potential candidate pathway linking these responses is the Janus kinase/ signal transduction and activator of transcriprition-3 (JAK/STAT3) pathway, with increasing evidence that this is a potential therapeutic target in cancer. In the present study, increased expression and nuclear localisation of STAT3 was associated with aberrant local and systemic inflammatory responses in patients undergoing resection of stage I-III colorectal cancer, and was associated with poorer survival. In addition to suggesting a role for JAK/STAT3 inhibitors in restoring host anti-tumour immune responses, the results of the present study further support the rationale for stratifying patients by host inflammatory responses in future trials of such agents.
Abstract Purpose
In patients with colorectal cancer (CRC), a high-density local inflammatory infiltrate response is associated with improved survival, whereas elevated systemic inflammatory responses are associated with poor survival. One potential unifying mechanism is the IL-6/JAK/STAT3 pathway. The present study examines the relationship between tumour total STAT3 and phosphorylated STAT3 Tyr705 (pSTAT3) expression, host inflammatory responses and survival in patients undergoing resection of stage I-III CRC.
Experimental Design
Immunohistochemical assessment of STAT3/pSTAT3 expression was performed using a tissue microarray and tumour cell expression divided into tertiles using the weighted histoscore. The relationship between STAT3/pSTAT3 expression and local inflammatory (CD3 + , CD8 + , CD45R0 + , FOXP3 + T-cell density and Klintrup-Mäkinen grade) and systemic inflammatory responses and cancer-specific survival were examined.
Results
196 patients were included in the analysis. Cytoplasmic and nuclear STAT3 expression strongly correlated (r=0.363, P<0.001); nuclear STAT3 and pSTAT3 expression weakly correlated (r=0.130, P=0.068). Cytoplasmic STAT3 was inversely associated with the density of CD3+ (P=0.012), CD8+ (P=0.003) and FOXP3+ T-lymphocytes (P=0.002) within the cancer cell nests and was associated with an elevated systemic inflammatory response as measured by modified Glasgow Prognostic Score (mGPS2: 19% vs. 4%, P=0.004).
The combination of nuclear STAT3/pSTAT3 stratified five-year survival from 81% to 62% (P=0.012), however was not associated with survival independent of venous invasion, tumour perforation or tumour budding.
Conclusion
In patients undergoing CRC resection, STAT3 expression was associated with adverse host inflammatory responses and reduced survival. Up-regulation of tumour STAT3 may be an important mechanism whereby the tumour deregulates local and systemic inflammatory responses.
INTRODUCTION
Colorectal cancer is the second most common cause of cancer death in Europe.
Despite improved outcomes over the past decades, survival still remains poor, with 5-year survival of around 50% across all disease stages (1) . Indeed, it is clear that the present TNMbased staging of colorectal cancer is suboptimal, with a need to identify characteristics pertaining to both the tumour and the host which may not only guide prognosis, but also the need for existing and novel adjuvant therapies.
One such characteristic is tumour-associated inflammation, which is now undisputed as impacting on both the development and progression of cancer (2) . In patients with colorectal cancer, for example, host local and systemic inflammatory responses are important determinants of disease progression, and their assessment is now accepted as holding independent prognostic value. To date, over 100 studies have examined the role of the local inflammatory cell infiltrate in determining outcome in patients with colorectal cancer (3), with a consistent, stage-independent decrease in disease recurrence and increase in survival observed in association with the presence of a conspicuous inflammatory cell infiltrate (3, 4) .
In contrast, an elevated systemic inflammatory response is associated with increased risk of recurrence and reduced survival across a number of cancers including colorectal cancer (5). Up-regulation of the systemic inflammatory response, as characterised by dysregulation of circulating pro-inflammatory cytokines, acute phase proteins such as Creactive protein (CRP) and albumin (6) , and myeloid cells (7, 8) , propagates a systemic environment which favours tumour growth and metastasis (9) . Furthermore, routine assessment of the systemic inflammatory response utilising routinely available biomarkers, such as acute phase proteins and components of the differential white cell count, informs prognosis complimentary to current TNM-based staging (8, 10) .
One potential mechanism linking the local and systemic inflammatory responses is activation of the Janus-activated kinase/ signal transduction and activator of transcription-3
(JAK/STAT3) pathway by interleukin-6 (IL-6). Circulating IL-6 is commonly elevated in a number of cancers, including colorectal cancer (11) (12) (13) , and is the predominant stimulus for the hepatic synthesis of acute phase proteins, including CRP (6). Cancer-associated fibroblasts and inflammatory cells contribute to high levels of IL-6 within the tumour microenvironment (14, 15) , with subsequent tumour cell activation of the soluble IL-6 receptor/ glycoprotein 130 complex (16) . Interleukin-6 trans-signalling regulates JAK activity within the tumour cell to promote phosphorylation of the tyrosine 705 residue of STAT3. Phosphorylated STAT3 (pSTAT3) translocates to the nucleus where it is a key transcription factor for numerous T h 2-type cytokines, including IL-6 (12, 14) , which promote a pro-tumour, immunosuppressive environment and attenuate host anti-tumour immune responses (15, 17) . Indeed, given its role in not only de-regulation of the host anti-tumour immune response, but also in orchestrating numerous pro-oncogenic processes (15, 18, 19) , it is not surprising that STAT3 expression and activation has previously been associated with reduced survival in a number of gastrointestinal cancers, including colorectal cancer (20) .
We hypothesise that the host systemic and local inflammatory responses in patients with colorectal cancer may be linked by STAT3. As such, the aim of the present study was to examine the relationship between tumour cell STAT3 expression, host local and systemic inflammatory responses and survival in a cohort of patients undergoing potentially curative, elective resection of stage I-III colorectal cancer. were defined using the modified Glasgow Prognostic Score (mGPS), the neutrophil:
MATERIALS AND METHODS
lymphocyte ratio (NLR) and the neutrophil: platelet score (NPS). The mGPS was calculated as previously described (10); patients with CRP ≤10mg/L were allocated a score of 0, patients with CRP >10mg/L and albumin ≥35g/L were allocated a score of 1, and patients with CRP >10mg/L and albumin <35g/L were allocated a score of 2. On the basis of previously published thresholds, NLR>5 was considered elevated (7). The NPS was calculated as previously described (22); patients with a platelet count<400x10 9 /L and neutrophil count<7. 5x10 9 /L were allocated a score of 0, either a neutrophil count>7.5x10 9 /L or platelet count>400x10 9 /L a score of 1, and those with both an elevated neutrophil and platelet count a score of 2.
Assessment of tumour microenvironment
The tumour-associated stroma, the generalised local inflammatory cell infiltrate and tumour budding have previously been characterised in this cohort using full haematoxylin & eosin (H&E)-stained sections of the deepest point of invasion according to previously published methodology (23) (24) (25) (26) . The tumour-associated stroma was assessed using tumour stroma percentage (TSP) and graded as either low (≤50%) or high (>50%) (25) . The local inflammatory cell infiltrate was assessed using the Klintrup-Mäkinen (KM) grade and graded as either low-grade (no increase or mild/patchy increase in inflammatory cells at invasive margin) or high-grade (prominent band-like inflammatory reaction or florid cup-like inflammatory reaction at invasive margin with destruction of cancer cell islands) (27) .
Tumour budding was examined using the 10-high powered field method as previously described Tumour budding was examined using the 10-high powered field method as previously described (26 
Assessment of STAT3 expression
Immunohistochemical assessment of tumour cell STAT3 activity was performed using a previously constructed colorectal cancer TMA consisting of four 0.6mm cores per patient (28) . The TMA was constructed from formalin fixed paraffin embedded tissue blocks corresponding to the full sections utilised for assessment of the tumour microenvironment. In addition to activation of STAT3 by phosphorylation of the tyrosine 705 residue by IL-6/JAK activation, activation may also occur through phosphorylation of the serine 727 residue in response to MAPK activation (29) . As the present study hypothesised an association between the systemic and local inflammatory response via IL-6/JAK/STAT3 activation, only total STAT3 expression and phosphorylated STAT3 Tyr705 (pSTAT3) expression was measured.
Sections were dewaxed in xylene before being rehydrated using graded alcohols. Antigen retrieval was performed using a citrate buffer at 96 o C for 20 minutes for STAT3, and using a Tris-EDTA buffer at high pressure in a microwave for 5 minutes for pSTAT3. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 10 minutes before rinsing in water. Casein and 5% horse serum in TBS were applied for 20 minutes at room temperature as a blocking agent for STAT3 and pSTAT3 respectively. Sections were then incubated overnight at 4 o C with the primary antibody (STAT3: product code 9132, Cell Signaling
Technologies; pSTAT3: product code 9131, Cell Signaling Technologies) at a concentration of 1:100 and 1:50 for STAT3 and pSTAT3 respectively before washing in TBS for ten minutes. Envision (Dako) was then added to the sections for 30 minutes at room temperature before washing in TBS for ten minutes. DAB substrate was added for five minutes until colour developed before washing in running water for ten minutes. Slides were counterstained in haematoxylin for 60 seconds and blued with Scotts' tap water before dehydration through graded alcohols. Cover slips were applied using distrene, plasticizer, xylene.
Sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) at x20 magnification and visualization was carried out using Slidepath Digital Image Hub (Slidepath, Leica Biosystems, Milton Keynes, UK). Assessment of STAT3 and pSTAT3 expression within the cancer cell cytoplasm and nucleus was performed at x20 magnification by a single examiner (J.H.P) blinded to clinical using the weighted histoscore (30) . To ensure reproducibility of scoring, 15% of tumours were co-scored by a second investigator (J.C.); the intraclass correlation coefficient was 0.826 and 0.837 respectively. For the purposes of the present study, cytoplasmic STAT3 expression was considered representative of total STAT3 expression whereas nuclear STAT3 and pSTAT3 expression were considered representative of STAT3 transcriptional activity.
Assessment of mismatch repair status
Mismatch repair (MMR) protein deficiency was determined using the TMA utilised for STAT3 assessment. Sections were stained for MLH1, MSH6, MSH2 and PMS2 (product codes: M3640, M3646, M3639 and M3647, respectively; Dako UK Ltd, Cambridgeshire, UK) as described previously (31 
Statistical analysis
For the purpose of statistical analysis, patients were divided into tertiles (low/ moderate/ high) on the basis of cytoplasmic and nuclear STAT3 and pSTAT3 expression as measured by h-score. The relationship between clinicopathological characteristics and cytoplasmic and nuclear STAT3 expression was examined using the Chi-square test for linear trend. The relationship between STAT3 expression and five-year cancer-specific survival was examined using Kaplan-Meier log-rank analysis and displayed as percentage surviving (standard error). The relationship between STAT3 expression, clinicopathological characteristics and cancer-specific survival was examined using Cox proportional hazards regression; variables with a P≤0.1 on univariate analysis were entered into a multivariate model using a backwards conditional model to calculate hazard ratios (HR) and 95% confidence intervals (CI). Given the number of comparisons performed, a P-value ≤0.01 was considered statistically significant for Chi-square analysis, with a P-value ≤0.05 considered statistically significant for survival analysis. All analyses were performed using SPSS version
(IBM SPSS).

RESULTS
A total of 196 patients who underwent elective, potentially curative resection of stage I-III colorectal cancer were included. Clinicopathological characteristics are displayed in Expression of STAT3 was observed in both the cytoplasm and nucleus, whereas The relationship between STAT3 and pSTAT3 expression tertiles and clinicopathological characteristics is displayed in Table 1 . Cytoplasmic expression of STAT3
was not associated with any clinicopathological characteristics. Although failing to reach statistical significance (P≤0.01), nuclear STAT3 expression showed an inverse association with use of adjuvant chemotherapy (P=0.038), whereas pSTAT3 expression was associated with younger age were younger (P=0.026) and an increased prevalence of lymph node positive disease (low pSTAT3 expression -35% vs. high pSTAT3 expression -52%,
P=0.039).
The relationship between STAT3 and pSTAT3 expression and components of the tumour microenvironment is displayed in The relationship between STAT3 and pSTAT3 expression and systemic inflammatory responses is displayed in Table 3 . Cytoplasmic STAT3 expression was associated with the systemic inflammatory response as measured by mGPS; this was predominantly due to an increase in the number of patients with mGPS=2 (high expression -19% vs. low expression 4%, P=0.004). Neither cytoplasmic nor nuclear STAT3 expression were associated with the systemic inflammatory response as measured by circulating platelets or components of the differential white cell count. Nuclear pSTAT3 expression was not associated with any measures of the systemic inflammatory response.
The median follow-up of survivors was 143 months (range 101-204) with 57 cancerassociated deaths and 64 non-cancer deaths. For the purposes of survival analysis, low and moderate expression of each marker was combined to form one group (low expression). The relationship between cytoplasmic STAT3, nuclear STAT3 and nuclear pSTAT3 and cancerspecific survival is displayed in Figure 1 and in Table 4 . High nuclear STAT3 expression was associated with poorer cancer-specific survival (P<0.05). High expression of both cytoplasmic STAT3 expression and nuclear pSTAT3 expression showed a non-significant trend towards poorer survival (P=0.068 and P=0.116 respectively).
To examine the relationship between expression and activation of STAT3 and survival, the cumulative prognostic value of cytoplasmic STAT3, nuclear STAT3 and nuclear pSTAT3 was examined with respect to five-year cancer-specific survival (Table 4 ). Three models were examined: model 1 (cytoplasmic STAT3/ nuclear STAT3) stratified survival from 81% (low expression of both) to 63% (high expression of both) (P=0.022), model 2
(cytoplasmic STAT3/ nuclear pSTAT3) stratified survival from 81% to 54% (P=0.018), and model 3 (nuclear STAT3/ nuclear pSTAT3) stratified survival from 81% to 62% (P=0.012).
When the three models were entered into a multivariate model using a backwards conditional method, only model 3 (nuclear STAT3/ nuclear pSTAT3) remained independently associated with cancer-specific survival (HR 1.63, 95%CI 1.14-2.34 P=0.008, Figure 1 ).
The relationship between this prognostic model and cancer-specific survival was examined on multivariate analysis. As the prognostic value of the Klintrup-Mäkinen grade has previously been shown to be similar to assessment of individual T-lymphocyte subsets (24) , only Klintrup-Mäkinen grade was entered into the multivariable model. On multivariate survival analysis (Table 5) Although failing to reach statistical significance, the density of tumour-associated stroma, as measured by TSP, appeared to be associated with pSTAT3 expression. Given that an increase in TSP primarily reflects an increased population of cancer-associated fibroblasts within the tumour microenvironment, this would further support the importance of IL-6 secretion by fibroblasts in the activation of the JAK/STAT3 pathway in tumour cells (14, 15) .
Indeed, the present results suggest that the JAK/STAT3 pathway may be an important mechanism by which the tumour influences the composition of the tumour microenvironment and deregulates host anti-tumour immune responses.
The present study found that increased tumour STAT3 expression was associated with elevated systemic inflammatory responses as measured using the mGPS, a cumulative score based on serum CRP and albumin concentrations. Such routinely measured biomarkers of the systemic inflammatory response represent only "the tip of a far larger iceberg" of cancerassociated systemic inflammation, whereby circulating cytokines, growth factors and myeloid-derived cells promote cancer progression and dissemination (9) . One such cytokine, IL-6, is commonly elevated in colorectal cancer (11, 13) , and is the main determinant of hepatic synthesis of CRP and responsible for the acute phase reduction in hepatic albumin synthesis (6) . Given the importance of IL-6 as both an activator of the JAK/STAT3 pathway and as an end product of its activation, the present results are perhaps not surprising, and suggest that STAT3 activation may play a role in the systemic inflammatory response in colorectal cancer.
However, although STAT3 expression was associated with an elevated mGPS, it was not associated with components of the differential white cell count. This is in keeping with previous work from Guthrie and colleagues, whereby serum IL-6 concentration correlated strongly with the mGPS but not the NLR in patients with colorectal cancer (13) . However, other groups have found contradictory results, with a positive association between serum IL-6 concentrations and the NLR in patients with colorectal cancer. This disparity may be explained by differences in the groups studied; whereas the patients in the present study and Although activation of the IL-6 receptor leads to rapid accumulation of STAT3, mechanistic studies have shown that less than 30% of total cytoplasmic STAT3 translocates to the nucleus on cytokine stimulation (42) . Furthermore, STAT3 also exhibits transcription-independent activity within the cytoplasm without nuclear translocation (42, 43) . Another plausible hypothesis is that rather than being directly causative, the presently observed associations In addition, assessment of the local and systemic environment held greater prognostic value than nuclear STAT3/pSTAT3 expression. Rather than being defined by one mechanism such as the JAK/STAT3 pathway, characteristics within the tumour microenvironment and the systemic inflammatory response are likely to be multifactorial in origin. Therefore, it might be anticipated that such phenotypic characteristics would be of greater prognostic value than a single signal transduction pathway. Indeed, it would be of considerable interest to examine and compare other signal transduction pathways associated with inflammation, such as the NF-κB pathway (46, 47) , in future studies.
The present study provides further clinical evidence of the role of the IL-6/JAK/STAT3 pathway in the amelioration of host anti-tumour immune responses, and raises two interesting points that remain to be investigated. Firstly, it would suggest a role for inhibitors of the IL-6/JAK/STAT3 pathway in restoring anti-tumour immune responses in patients with colorectal cancer (48, 49) . Secondly, it would support the hypothesis that routine markers of the systemic inflammatory response, and in particular the mGPS, may aid in the identification and selection of patients likely to benefit from such targeted therapies (50) . In keeping with such a scheme, one recent clinical trial of a JAK inhibitor in patients with metastatic pancreatic cancer found an increase in overall survival only in those patients with an elevated CRP or mGPS (51) . Therefore, it is clear that markers of the host inflammatory response should be incorporated into future studies of agents targeting the IL-6/JAK/STAT3 pathway in cancer.
Given the increasing appreciation of distinct molecular subtypes of colorectal cancer (52) , the results of the present study are perhaps limited by the lack of molecular characterisation of the tumours studied. Although not associated with MMR status in the present cohort, the relationship between STAT3 and other characteristics, such as KRAS and BRAF status, would be of interest. However, a previous comprehensive study by Morikawa and colleagues found no association between STAT3, a number of molecular characteristics and survival in a cohort of over 700 patients (33) . Furthermore, it has also been suggested that STAT3 may have a role in not only induction of KRAS mutated tumours (53), but also in conferring chemoresistance in patients with KRAS wild-type tumours (54) . Indeed, this would suggest that STAT3 is independent of such characteristics. A further limitation is the relatively small sample size, precluding meaningful subgroup analysis. Analysis was restricted to a previously constructed TMA, and only patients who had complete staining for both STAT3 and pSTAT3 were included. However, post-hoc power calculation shows that the present study has adequate power to examine the relationship between STAT3 and the local and systemic environment. For example, post-hoc analysis suggests that the present study holds 84% power to determine a difference in cancer cell nest CD8 + T-lymphocyte density between those with low and high cytoplasmic STAT3 expression.
In conclusion, the results of the present study suggest a relationship between tumour cell STAT3 expression and the host inflammatory response, and may be one potential mechanism whereby the tumour promotes a local and systemic environment amenable to tumour growth and dissemination. Further studies are required to confirm such a relationship, and whether therapeutic targeting of the IL-6/JAK/STAT3 may be utilised in the treatment of patients with colorectal cancer and elevated systemic inflammatory responses.
Table 1
The relationship between tumour cell STAT3 and pSTAT3 expression and clinicopathological characteristics of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 72 (37) 61 (31) 63 (32) 23 (30) 29 (38) 24 (32) 22 (39) 18 (32) 16 (29) 27 (42) 14 (22) 23 (36) 0.571 29 (39) 25 (33) 21 (28) 25 (37) 22 (33) 10 (29) 18 (33) 14 (26) 23 (41) 0.199 19 (26) 23 (32) 30 (42) 26 (43) 19 (31) 16 (26) 27 (43) 19 (30) 17 (27) 0.026
Sex Female Male
94 (48) 102 (52) 40 (53) 36 (47) 21 (37) 35 (63) 33 (52) 31 (48) 0.833 35 (47) 40 (53) 31 (47) 35 (53) 28 (51) 27 (49) 0.647 38 (53) 34 (47) 23 (38) 38 (62) 33 (52) 30 (48) 0.906
Adjuvant therapy No Yes
142 (72) 54 (28) 55 (72) 21 (28) 44 (79) 12 (21) 43 (67) 21 (33) 0.532 48 (64) 27 (36) 50 (76) 16 (24) 44 (80) 11 (20) 0.038 56 (78) 16 (22) 41 (67) 20 (33) 45 (71) 18 (29) 0.389
Tumour characteristics Tumour location Colon Rectum
130 (66) 66 (34) 48 (63) 28 (37) 37 (66) 19 (34) 45 (70) 19 (30) 0.375 47 (63) 28 (37) 43 (65) 23 (35) 40 (73) 15 (27) 0.242 49 (68) 23 (32) 37 (61) 24 (39) 44 (70) 19 (30) 0.860
T stage 1-2 3 4
25 (13) 121 (61) 50 (26) 10 (13) 49 (65) 17 (22) 9 (16) 34 (61) 13 (23) 6 (9) 38 (59) 20 (31) 0.288 10 (13) 46 (61) 19 (25) 10 (15) 41 (62) 15 (23) 5 (9) 34 (62) 16 (29) 0.480 10 (14) 43 (60) 19 (26) 8 (13) 39 (64) 14 (23) 7 (11) 39 (62) 17 (27) 0.694 (8) 94 (48) 86 (44) 6 (8) 41 (54) 29 (38) 7 (13) 23 (41) 26 (46) 3 (5) 30 (47) 31 (48) 0.211 6 (8) 28 (37) 41 (55) 8 (12) 38 (58) 20 (30) 2 (4) 28 (50) 25 (46) 0.494 7 (10) 40 (55) 25 (35) 5 (8) 28 (46) 28 (46) 4 (6) 26 (41) 33 (52) 0.051
Tumour differentiation Mod/well Poor
174 (89) 22 (11) 69 (91) 7 (9) 49 (87) 7 (13) 56 (87) 8 (13) 0.530 63 (84) 12 (16) 60 (91) 6 (9) 51 (93) 4 (7) 0.108 60 (83) 12 (17) 57 (93) 4 (7) 57 (91) 6 (10) 0.174
Venous invasion No Yes
129 (66) 67 (34) 51 (67) 25 (33) 39 (70) 17 (30) 39 (61) 25 (39) 0.465 46 (61) 29 (39) 45 (68) 21 (32) 38 (69) (22) 43 (78) 12 (22) 44 (69) 20 (31) 0.241 56 (75) 19 (25) 51 (77) 15 (23) 39 (72) 15 (28) 0.794 55 (78) 16 (22) 50 (82) 11 (18) 40 (64) 22 (36) 0.090
Tumour budding (182) Low High
45 (64) 25 (36) 40 (74) 14 (26) 38 (65) 20 (35) 0.834 45 (63) 26 (37) 44 (76) 14 (24) 34 (64) 19 (36) 0.822 49 (75) 16 (25) 41 (71) 17 (29) 33 (56) 26 (44) 0.022
Low High 36 (49) 37 (51) 30 (60) 20 (40) 35 (57) 26 (43) 0.332 37 (51) 35 (49) 28 (46) 33 (54) 36 (71) 15 (29) 0.055 34 (54) 29 (46) 31 (52) 28 (48) 36 (58) (48) 27 (51) 26 (49) 31 (52) 29 (48) 0.960 33 (47) 38 (54) 31 (48) 33 (52) 32 (63) 19 (37) 0.089 32 (48) 38 (52) 29 (50) 29 (50) 37 ( (49) 29 (56) 23 (44) 38 (62) 23 (38) 0.180 39 (53) 34 (47) 34 (54) 29 (46) 31 (62) 19 (38) 0.373 40 (60) 27 (40) 32 (54) 27 (46) 32 (53) 28 (47) 0.466
FOXP3 + cancer cell nest density (188) Low High
26 (36) 47 (64) 26 (49) 27 (51) 39 (63) 23 (37) 0.002 39 (53) 34 (47) 25 (39) 39 (61) 27 (53) 24 (47) 0.807 38 (56) 30 (44) 26 (44) 33 (56) 27 (44) 34 (56) 0.181 Table 3 The relationship between tumour cell STAT3 and pSTAT3 expression and systemic inflammatory responses of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer Table 4 Relationship between tumour cell STAT3 and pSTAT3 expression and cancer-specific survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer Table 5 Relationship between combined tumour cell nuclear STAT3/ pSTAT3 expression, clinicopathological characteristics and cancer-specific survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer 
